Skip to main content
SpringerLink
Log in

Rosuvastatin calcium

  • Fresh from the Pipeline
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

Rosuvastatin calcium (Crestor; AstraZeneca), the seventh drug in the statin class, was approved by the US FDA in August 2003 for the reduction of cholesterol levels in patients with hypercholesterolaemia. Billed as the most potent statin available, can it overcome initial setbacks and make a significant impact in the multi-billion-dollar market for cholesterol-lowering drugs?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Rosuvastatin calcium.
Figure 2: Market for drugs to treat dyslipidaemia in US $ billion.

References

  1. Tobert, J. A. Lovastatin and beyond: the history of the 1HMG-CoA reductase inhibitors. Nature Rev. Drug Discov. 2, 517–526 (2003).

    Article  CAS  Google Scholar 

  2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo controlled trial. Lancet 360, 7–22 (2002).

  3. Sever, P. S. for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149–1158 (2003).

    Article  CAS  Google Scholar 

  4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421 (2002).

  5. Watanabe, M. et al. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptonates, a novel series of HMG-CoA reductase inhibitors. Bioorg. Med. Chem. 5, 437–444 (1997).

    Article  CAS  Google Scholar 

  6. FDA Drug Approvals List [online] (cited 26 Aug 2003). <http://www.fda.gov/cder/foi/label/2003/21366_crestor_lbl.pdf> (2003).

  7. Jones, P. H. et al. for the STELLAR study group. Statin therapies for elevated lipid levels compared across dose ranges to rosuvastatin: low-density lipoprotein cholesterol and high density lipoprotein cholesterol results. J. Am. Coll. Cardiol. 92, 152–160 (2003).

    Article  CAS  Google Scholar 

  8. Earl, J. & Kirkpatrick, P. Ezetimibe. Nature Rev. Drug Discov. 2, 97–98 (2003).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Drug Discovery,

    Peter Kirkpatrick

  2. Decision Resources Intl, 50–51 Russell Square, London, WC1B 4HQ, UK

    Jeremy Quirk & Mark Thornton

Authors
  1. Jeremy Quirk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Thornton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeremy Quirk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Quirk, J., Thornton, M. & Kirkpatrick, P. Rosuvastatin calcium. Nat Rev Drug Discov 2, 769–770 (2003). https://doi.org/10.1038/nrd1205

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1205

  • Springer Nature Limited

This article is cited by

Search

Navigation